Crossject is now eligible for France's PEA-PME investment scheme, benefiting retail investors with tax advantages.

From GlobeNewswire: 2024-09-26 01:30:00

Crossject, a specialty pharma company, is now eligible for PEA-PME, a French government investment scheme for retail investors to purchase European securities with tax benefits. To qualify, companies must have a market cap under €1 billion, fewer than 5,000 employees, and an annual turnover under €1.5 billion. Crossject is known for its needle-free auto-injector ZENEO platform and is developing emergency medicines like ZEPIZURE for epileptic rescue therapy. The company also has a contract with BARDA worth $60 million. For more info, contact Natasha Drapeau for investors or Sophie Baumont for media.



Read more at GlobeNewswire: Crossject announces its eligibility for France’s PEA-PME